Amarin's Vascepa shows OS benefit in colorectal cancer trial

October 25, 2026 8:11 AM

Amarin Corporation (NASDAQ: AMRN) reported results from the Phase 3 EPA for Metastasis Trial 2 (EMT2), a University of Leeds-sponsored ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found